Novel insights into the treatment of SARS-CoV-2 infection: An overview of current clinical trials

Abstract

The emergence of the global pandemic caused by the novel SARS-CoV-2 virus has motivated scientists to find a definitive treatment or a vaccine against it in the shortest possible time. Current efforts towards this goal remain fruitless without a full understanding of the behavior of the virus and its adaptor proteins. This review provides an overview of the biological properties, functional mechanisms, and molecular components of SARS-CoV-2, along with investigational therapeutic and preventive approaches for this virus. Since the proteolytic cleavage of the S protein is critical for virus penetration into cells, a set of drugs, such as chloroquine, hydroxychloroquine, camostat mesylate have been tested in clinical trials to suppress this event. In addition to angiotensin-converting enzyme 2, the role of CD147 in the viral entrance has also been proposed. Mepolizumab has shown to be effective in blocking the virus's cellular entrance. Antiviral drugs, such as remdesivir, ritonavir, oseltamivir, darunavir, lopinavir, zanamivir, peramivir, and oseltamivir, have also been tested as treatments for COVID-19. Regarding preventive vaccines, the whole virus, vectors, nucleic acids, and structural subunits have been suggested for vaccine development. Mesenchymal stem cells and natural killer cells could also be used against SARS-CoV-2. All the above-mentioned strategies, as well as the role of nanomedicine for the diagnosis and treatment of SARS-CoV-2 infection, have been discussed in this review.

Recurrent SARS-CoV-2 infection resulting in acute respiratory distress syndrome and development of pulmonary hypertension: A case report

“…Inflammatory markers were significant for sedimentation rate 72, C-reactive protein 10.8, fibrinogen 601, d-dimer 2.035, ferritin 804, and lactate dehydrogenase 508. She was started on dexamethasone, remdesevir, ceftriaxone, azithromycin, vitamin C, and zinc 6 . table 1 .…”

Acute and post-acute phase of COVID-19: Analyzing expression patterns of miRNA-29a-3p, 146a-3p, 155-5p, and let-7b-3p in PBMC

“…Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which belongs to the family Coronaviridae , subfamily Coronavirinae , genus Betacoronavirus is the causative agent of COVID-19 disease. This virus was known as the cause of pneumonia cases in late 2019 in Wuhan, China [1] , [2] , [3] . The pandemic of SARS-CoV-2 is spread to more than 200 countries in the world and has been the causative agent for the death of over 2 million people.…”

SARS-CoV-2 infection: The role of PD-1/PD-L1 and CTLA-4 axis

“…SARS-CoV-2 is a single-stranded RNA (ss-RNA) virus with the largest genome among RNA-viruses with a length of 29,903 nucleotides. The virus is coated with prominent, crown-like proteins on its surface that induces immune responses [ [6] , [7] , [8] ]. Similarly, this virus, like the two other viruses, SARS-CoV and MERS-CoV, utilize ACE2 (angiotensin-converting enzyme 2) as a receptor to enter the target cells [ 3 , 6 ].…”